IHC validation demonstrated that ST3GAL4 overexpression in TNBC tissues predicts poor clinical outcomes.<h4>Conclusions</h4>ST3GAL4-driven glycosphingolipid metabolism promotes tumor immune evasion and aggressiveness in TNBC. Here, ST3GAL4 is linked to neoplasm.